All In Biotech

Drug Trial Radar · NCT03362684

PETACC-8 miR-31-3p and miR-31-5p Ancillary Study

Ancillary Study of miR-31-3p and miR-31-5p Expression Levels in Patients Enrolled in the PETACC-8 Study, and of the Predictive Role of miR-31-3p Expression Level on Clinical Outcomes of Patients Treated With Cetuximab

Last checked: Nov 20, 2026Latest source record: Dec 5, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,808 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,808

Actual

Start

Nov 2005

Primary completion

Nov 2009

Study completion Jun 30, 2016

Sponsor

Lead sponsor
IntegraGen SAIndustry
Sponsor type
Industry
Collaborators
Federation Francophone de Cancerologie Digestive; Exystat
First posted
Dec 5, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 74 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective-retrospective study to determine if the expression of the miRNA's miR-31-3p and miR-31-5p are prognostic of patient outcomes or predictive of the benefit from anti-EGFR therapy in stage III Colon Cancer. The present study will utilize FFPE tumor samples collected from patients enrolled in the PETACC-8 study conducted by the Fédération Francophone de Cancérologie Digestive (FFCD). This phase 3 clinical trial prospectively randomized fully resected stage III colon cancer patients to receive adjuvant treatment with either FOLFOX-4 plus cetuximab or FLOFOX-4 alone.

Conditions

  • Colorectal Cancer

Interventions

  • CetuximabDrug

    Cetuximab every 2 weeks

  • FOLFOXDrug

    FOLFOX-4 every 2 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease Free Survival (DFS)Time frame: From date of randomization until the date of first documented any signs or symptoms cancer relapse or date of death, whichever came first, assessed up to 7 years
  2. Prognostic and predictive value of miR-31-3p expression on Disease Free Survival (DFS)Time frame: From date of randomization until the date of first documented any signs or symptoms cancer relapse or date of death, whichever came first, assessed up to 7 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.